Portela becomes first mAb therapy with a three-month dosing interval approved for the alleviation of pain associated with OA ...

Abstract: Non-orthogonal multiple access (NOMA) is an attractive multiple access technique to achieve the optimal system capacity region. A great deal of recent ...